Catabasis Pharmaceuticals, a US-based healthcare company treating inflammation, has extended its series A round by $8m to take its total raised to $47.6m from a consortium including drugs group AstraZeneca’s MedImmune Ventures corporate venturing unit.
All other current investors participated in the third financing extension, including venture capital firms SV Life Sciences, Clarus Ventures and Advanced Technology Ventures.